Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 6/13/2025

Polyneuropathy Treatment Guidelines

Initial Treatment and Diagnosis

  • The American College of Cardiology recommends starting with pregabalin or gabapentin for patients with polyneuropathy, with a starting dose of 75 mg twice daily for pregabalin and 300 mg at bedtime for gabapentin, with gradual titration to a goal of 300 mg/day (up to 600 mg/day if needed) for pregabalin and 1800 mg/day (up to 3600 mg/day) for gabapentin 1
  • Before initiating treatment, it's essential to determine the type and cause of polyneuropathy through laboratory screening, including HbA1c, vitamin B12, folate, TSH, serum protein electrophoresis, immunofixation, and CPK 2
  • Additional testing, such as ANA, ESR, CRP, hepatitis B/C, HIV, and Lyme disease, should be considered based on clinical presentation 2
  • Imaging, such as MRI of the spine with or without contrast, should be considered if radicular symptoms are present 3
  • Electrodiagnostic studies, including nerve conduction studies (NCS) and electromyography (EMG), should be considered to characterize the neuropathy 4

Medication Management

  • Pregabalin should be started at 75 mg twice daily, with gradual titration to a goal of 300 mg/day (up to 600 mg/day if needed), with dosage adjustment needed in renal insufficiency, and monitoring for sedation, dizziness, peripheral edema, and weight gain 1
  • Gabapentin should be started at 300 mg at bedtime, with increase every 4-7 days by 300 mg increments to a goal of 1800 mg/day (up to 3600 mg/day), with divided doses and dosage adjustment needed in renal insufficiency 1
  • Duloxetine should be started at 20-30 mg once daily, with increase weekly to a goal of 60 mg/day, with maximum 120 mg/day (split twice daily), and caution with hepatic failure and risk of serotonin syndrome 1
  • Tricyclic antidepressants, such as nortriptyline or amitriptyline, should be used with caution in patients with cardiac disease or dysrhythmias, and started at 10-25 mg at bedtime, with increase every 4-7 days to a goal of 25-75 mg at bedtime 1, 5

Treatment Approach

  • The treatment approach should involve starting with pregabalin or gabapentin, and if inadequate response after 4-8 weeks, adding or switching to duloxetine, and if still inadequate, considering tricyclic antidepressants (if no contraindications) 1, 6
  • Regular assessment of pain and function should be done every 2-4 weeks during initial titration, with monitoring for medication-specific adverse effects, and adjustment of dosing based on efficacy and tolerability 1
  • Inflammatory neuropathies require immunomodulatory treatment rather than just symptomatic management, and regular assessment of strength, sensation, and disability scores should be done 4

Common Pitfalls

  • Inadequate dosing and insufficient trial duration are common pitfalls in treating polyneuropathy, with many patients receiving subtherapeutic doses of neuropathic pain medications, and treatment failure should not be declared until 6-8 weeks at target dose 1
  • Overlooking treatable causes and ignoring comorbidities, such as cardiac disease, renal function, and fall risk, can also lead to inadequate treatment 1, 5